Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 28;10(21):5162-5172.
doi: 10.7150/jca.36300. eCollection 2019.

Update on current pancreatic treatments: from molecular pathways to treatment

Konstantinos Sapalidis  1 , Christoforos Kosmidis  1 , Varvara Funtanidou  2 , Athanasios Katsaounis  1 , Amastasios Barmpas  1 , Georgios Koimtzis  1 , Stylianos Mantalobas  1 , Vyron Alexandrou  1 , Zoi Aidoni  1 , Charilaos Koulouris  1 , Efstathios Pavlidis  1 , Dimitrios Giannakidis  1 , Valeriu Surlin  1 , Stelian Pantea  3 , Victor Strambu  4 , Rogoveanu Otilia Constantina  5 , Aikaterini Amaniti  2 , Paul Zarogoulidis  1   2 , Stelian Mogoantă  6 , Isaak Kesisoglou  1 , Chrysanthi Sardeli  7
Affiliations
Review

Update on current pancreatic treatments: from molecular pathways to treatment

Konstantinos Sapalidis et al. J Cancer. .

Abstract

Pancreatic cancer is still diagnosed at a late stage although we have novel diagnostic tools. Pancreatic cancer chemotherapy treatment resistance is observed and therefore novel treatments are in need. Anti-cancer stem cell therapy, combination of chemotherapy and/or radiotherapy with immunotherapy, proteins/enzymes and gene therapy are currently under evaluation. Targeted treatment with tyrosine kinase inhibitors is also administered and novel inhibitors are also under evaluation. In the current review we present recent data from our search within the year 2018.

Keywords: cancer; gene therapy; pancreatic cancer; stem cells.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
MHC; major histocompatibility complex, TAA; tumor-associated antigens, CTLA4; cytotoxic T-lymphocyte-associated protein 4
Figure 2
Figure 2
From left to right; Radial esophageal ultrasound, convex probe and convex probe esophageal ultrasound
Figure 3
Figure 3
Pancreatic stem cells are used as a targeted therapy
Figure 4
Figure 4
The tyrosine kinase inhibitor blocks the tumor growth
See this image and copyright information in PMC

References

    1. Shrikhande SV, Kleeff J, Kayed H, Keleg S, Reiser C, Giese T. et al. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer research. 2006;26:3265–73. - PubMed
    1. Apollos JR, Sami S, Prasanth MN, Jeyakumar J, McFadyen AK. Pre-diagnostic delays caused by gastrointestinal investigations do not affect outcomes in pancreatic cancer. Annals of medicine and surgery. 2018;34:66–70. doi:10.1016/j.amsu.2018.07.011. - PMC - PubMed
    1. Zhang H, Zeng J, Tan Y, Lu L, Sun C, Liang Y. et al. Subgroup analysis reveals molecular heterogeneity and provides potential precise treatment for pancreatic cancers. OncoTargets and therapy. 2018;11:5811–9. doi:10.2147/OTT.S163139. - PMC - PubMed
    1. Keleg S, Buchler P, Ludwig R, Buchler MW, Friess H. Invasion and metastasis in pancreatic cancer. Molecular cancer. 2003;2:14. - PMC - PubMed
    1. Bolton NM, Maerz AH, Brown RE, Bansal M, Bolton JS, Conway WC. Multiagent neoadjuvant chemotherapy and tumor response are associated with improved survival in pancreatic cancer. HPB: the official journal of the International Hepato Pancreato Biliary Association. 2018 doi:10.1016/j.hpb.2018.08.013. - PubMed